BioSpace News Archive

Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference.

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2022.

VirtaMed’s VR simulations provide advanced training for surgeons using MMI’s Symani® Robotic System and introduce new product testing capabilities.

StageZero Life Sciences, Ltd., a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced that Matthew Pietras has resigned as CFO and COO.

Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the acceptance of an abstract for poster presentation at the upcoming 2022 ASCO Annual meeting in Chicago, IL from June 3-7, 2022.

Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will present at the Jefferies Healthcare Conference on June 8, 2022 at 10:00 AM ET.

Yingli Pharma US, Inc, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating YL-13027 a potent and selective TGFβ receptor 1 (TGFβR1) inhibitor.

Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Company management will participate in two upcoming investor conferences in June 2022.

ACTO, the only complete commercial learning platform for the life science industry, is strengthening its executive management team with two key additions to meet US demand.

At the 69th Annual Conference of the Israel Heart Society, UltraSight, and Sheba Medical Center Israel revealed new research findings from a blinded pilot study that validates the company’s technology, and confirms that UltraSight’s Artificial Intelligence (AI) guidance can allow any medical professional to successfully capture quality cardiac ultrasound images.